📰 Discovery Brain Sciences News
Page 6 - Discovery Brain Sciences News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Discovery Brain Sciences. Real-time updates on events, politics, business and more.
April 24, 2023
Researchers say the findings are a ‘significant’ step forward in demonstrating that it may be possible to target the protein to slow the disease.
April 14, 2023
ADULTS with hearing loss are 42 per cent less likely to develop dementia if they use a hearing aid, according to a major new study.
April 5, 2023
Alzheimers disease strikes women harder than men — over two-thirds of those who descend into dementias devastating twilight are female at birth. Thats likely due to biological reasons that remain
April 4, 2023
Alzheimers disease strikes women harder than men — over two-thirds of those who descend into dementias devastating twilight are female at birth. Thats likely due to biological reasons that remain
January 5, 2023
SynGAP Research Fund (SRF), a 501(c)(3) public charity whose mission is to improve the quality of life for SYNGAP1 patients through the research and development of treatments, therapies and support systems, along with SynGAP Research Fund UK, today announced they have awarded a $180,000 grant to the University of Edinburgh Medical School's Patrick Wild Centre & Centre for Discovery Brain Sciences to advance the science around gene transfer to correct SYNGAP1 haploinsufficiency.
December 1, 2022
CBS 58 is your local source for the Milwaukee news, Milwaukee weather, and Milwaukee sports.
December 1, 2022
Lecanemab has become one of the first experimental dementia drugs to appear to slow the progression of cognitive decline.
November 30, 2022
Antibody therapy lecanemab removes clumps of protein called beta amyloid that builds up in brain
November 30, 2022
Lecanemab has become one of the first experimental dementia drugs to appear to slow the progression of cognitive decline.
November 30, 2022
The experimental drug lecanemab shows "potential" as an Alzheimers disease treatment, according to new Phase 3 trial results, but the findings raise some safety concerns because of its association with